BioMarin Pharma (BMRN) Tops Q2 EPS by 2c, FY Guidance Unchanged
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Go back to BioMarin Pharma (BMRN) Tops Q2 EPS by 2c, FY Guidance Unchanged
August 5, 2015 6:44 AM EDT
Wedbush reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $139.00 (from $130.00), following Q2 earnings. Q2 revenues of $250.5MM beat consensus ($218.2MM). GAAP-EPS of $(0.55) was below consensus of $(0.53) due to high Op-Ex.
Analyst Liana Moussatos commented, "Q2... More
August 4, 2015 8:41 AM EDT
Piper Jaffray reiterated an Overweight rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $168.00 (from $163.00), following 2Q15 earnings results. Analyst Joshua Schimmer said that the results beat top and bottom line driven primarily by lumpy Naglazyme purchasing and reiterated... More
August 4, 2015 7:24 AM EDT
Nomura Securities analyst M. Ian Somaiya reiterated a Buy rating and lifted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $173.00 (from $163.00) following Q2 results, saying they are increasingly confident on Drisapersen.
Somaiya commented, "We are raising our BMRN TP to $173 from $163 following 2Q earnings which... More
